• AAPL 195.71
  • TSLA 243.84
  • AMZN 147.42
  • BTC-USD 43798.3711
  • ETH-USD 2355.0159
  • EURUSD 1.0764
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. NVSEF.US

Novartis AG (NVSEF PINK) stock market data APIs

$95.62 -0.38(-0.4%) as of December 8, 2023

Novartis AG Financial Data Overview

96
95.62
-
96
94.85
65.1385-99.69
198 879 M
24.8705
2 055 M
54 217 M
1.74
0.0357
0.491
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'NVSEF',
Type: 'Common Stock',
Name: 'Novartis AG',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000KSBX82',
ISIN: 'CH0012005267',
CUSIP: NULL,
CIK: '1114448',
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - General',
GicSector: NULL,
GicGroup: NULL,
GicIndustry: NULL,
GicSubIndustry: NULL,
HomeCategory: NULL,
IsDelisted: false,
}

Novartis AG Fundamental Data is available in our Financial Data APIs

  • Net Revenue 54 217 M
  • EBITDA 21 593 M
  • Earnings Per Share 3.86
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Novartis AG Earnings via APIs

  • Latest Release 2023-10-24
  • EPS/Forecast 1.67

Get Novartis AG End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Novartis AG latest news via APIs

Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions

Novartis Pharma AG With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefitan...

Pharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod

This week, AbbVie ABBV announced a definitive agreement to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion. The FDA approved Novartis’ NVS rare blood disorder drug, Fabhalta (ip...
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com